Researchers have developed an AI model that accurately predicts gene activity in any human cell, providing insights into ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

BITR-2101 is under clinical development by Boston Immune Technologies and Therapeutics and currently in Phase I for T-Cell Leukemia.

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the ...

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received ...

HealthDay News — For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T ...

The treatment for leukemia depends on many factors ... These are synthetic versions that are designed to attack cancer cells. For CLL, monoclonal antibodies are a mainstay of treatment, often combined ...

A similar study, also published earlier this year, showed promise for adults with leukemia ... He also has studied B-cell acute lymphoblastic leukemia. “… It’s incredibly important ...

Acute lymphoblastic leukemia (ALL) is a malignancy of lymphoid blood cells characterized by the immature lymphocytic ...